Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs ARSYNL Rx

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and ARSYNL Rx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 305 · Grade C

ARSYNL Rx

Visit ARSYNL Rx Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 63 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make ARSYNL Rx a bad call — it's best for readers comparing a clearly identified injection with other advertised routes who will verify the formulation and refill agreement. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
71
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
78
Track Record
88
65
CoreAge RxBrief Score 94 · 63ARSYNL Rx

Price, coverage & the tracker

CoreAge RxARSYNL Rx
Brief Score94/100 (A)63/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Injection page advertises $219/month

One-month compounded semaglutide + B12 plan; medication, provider review, supplies and delivery described included.

Selected dose and supplied quantity unconfirmed; earlier $233/month listing is historical. Exact refill cancellation deadline needs confirmation.

Full price details

Compounded semaglutide injection offered; complete selected-prescription quote unknown; current product page advertises $219/month one-month plan with medication and care, while earlier listing from $233/mo is historical

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Injection page advertises $269/month

One-month plan; product title says B12 while treatment body says B6. Confirm exact formulation and supplied quantity.

Earlier $366/month listing is historical. Transdermal spray is separate: $269/month or $759 once for three months, with a four-week bottle described.

Full price details

Compounded tirzepatide injection offered; exact added ingredient and complete selected-prescription quote unknown; current injection page advertises $269/month one-month plan but title says B12 and body says B6; earlier listing from $366/mo is historical

CoverageUS only; restrictions by state, confirmed at intakeU.S. service advertised; eligibility restrictions vary by therapy, medication and patient state
Brand-name accessNot confirmedReferences to Wegovy, Ozempic, Mounjaro or Zepbound ingredients and trial results do not establish an advertised branded prescribing program.
Oral / sublingualInjection onlyUnconfirmed
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

ARSYNL Rx: Current injection pages advertise $219/month semaglutide and $269/month tirzepatide; selected formulation/supply remain unconfirmed and tirzepatide B12/B6 wording conflicts. Spray is a separate route.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.